Screener
Design Therapeutics, Inc. DSGN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development (including related party amounts of $72 and $228, respectively) | $14,379 | $15,377 |
| General and administrative (including related party amounts of $85 and $134, respectively) | 5,327 | 5,041 |
| Total operating expenses | 19,706 | 20,418 |
| Loss from operations | (19,706) | (20,418) |
| Interest income | 2,070 | 2,703 |
| Net loss | $(17,636) | $(17,715) |
| Net loss per share, basic and diluted | $(0.29) | $(0.31) |
| Weighted-average shares of common stock outstanding, basic and diluted | 61,434,457 | 56,757,827 |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s operating income?
- Design Therapeutics, Inc. (DSGN) reported operating income of -$19.71M in Q1 2026.
- How has Design Therapeutics, Inc.'s operating income changed year-over-year?
- Design Therapeutics, Inc.'s operating income increased by 3.5% year-over-year, from -$20.42M to -$19.71M.
- What is the long-term trend for Design Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s operating income has grown at a 22.0% compound annual growth rate (CAGR), from -$35.83M to -$79.47M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Design Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude